Human epidermal growth factor receptor 2 (HER2) overexpression or amplification occurs in approximately 15% to 20% of patients with breast cancer, associated with poor prognoses and a median overall survival of 25 months [1, 2]. The gene discussed is ERBB2; the disease is breast carcinoma.